Rigel Pharmaceuticals is a biotechnology company focused on developing and commercializing novel therapies for hematologic disorders and cancer. Its FDA-approved products include TAVALISSE (fostamatinib), an oral SYK inhibitor for chronic ITP; REZLIDHIA (olutasidenib), for relapsed/refractory AML with IDH1 mutation; and GAVRETO (pralsetinib), for metastatic RET fusion-positive NSCLC and advanced thyroid cancer. Its pipeline includes R289, a dual IRAK1/4 inhibitor in Phase 1b for lower-risk MDS.
Q2 FY2026 — expected 2026-08-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-03 | 2025-12-31 | 0001034842-26-000015 | EDGAR | 99K words |
| 2025-03-04 | 2024-12-31 | 0001558370-25-002169 | EDGAR | — |
| 2024-03-05 | 2023-12-31 | 0001558370-24-002475 | EDGAR | — |
| 2023-03-07 | 2022-12-31 | 0001558370-23-003035 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001558370-22-002551 | EDGAR | — |
| 2021-03-02 | 2020-12-31 | 0001558370-21-002254 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001558370-20-001624 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0001558370-19-001310 | EDGAR | — |
| 2018-03-06 | 2017-12-31 | 0001558370-18-001555 | EDGAR | — |
| 2017-03-07 | 2016-12-31 | 0001558370-17-001428 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001104659-25-106268 | EDGAR | 73K words |
| 2025-08-05 | 2025-06-30 | 0001558370-25-010281 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001558370-25-006493 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014862 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001558370-24-011079 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-007041 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001558370-23-017987 | EDGAR | — |
| 2023-08-01 | 2023-06-30 | 0001558370-23-012722 | EDGAR | — |
| 2023-05-02 | 2023-03-31 | 0001558370-23-007653 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001558370-22-016266 | EDGAR | — |
| 2022-08-02 | 2022-06-30 | 0001558370-22-011638 | EDGAR | — |
| 2022-05-03 | 2022-03-31 | 0001558370-22-006809 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-03 | 0001034842-26-000016 | EDGAR | 4K words |
| 2026-02-03 | 0001034842-26-000007 | EDGAR | — |
| 2026-01-12 | 0001034842-26-000005 | EDGAR | — |
| 2025-12-10 | 0001104659-25-119976 | EDGAR | — |
| 2025-11-04 | 0001104659-25-106282 | EDGAR | — |
| 2025-08-05 | 0001104659-25-074163 | EDGAR | — |
| 2025-05-23 | 0001104659-25-052407 | EDGAR | — |
| 2025-05-06 | 0001104659-25-045067 | EDGAR | — |
| 2025-03-27 | 0001104659-25-028564 | EDGAR | — |
| 2025-03-10 | 0001104659-25-022224 | EDGAR | — |
324 total filings indexed. 292 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001034842 |
| Ticker | RIGL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.rigel.com |
| Listed | 2000-11-29 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report